Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2016 | Case report

Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner’s syndrome: report of two cases

Authors: Wei Li, Yuhong Zhou, Qian Li, Hanxing Tong, Weiqi Lu

Published in: World Journal of Surgical Oncology | Issue 1/2016

Abstract

Background

A minority of intra-abdominal desmoid tumors is associated with Gardner’s syndrome in which desmoid tumors become an important cause of morbidity and mortality if they are surgically unresectable.

Case presentation

Here, we report two cases of intestinal perforation during chemotherapy in patients with Gardner’s syndrome-associated intra-abdominal desmoids. One female and one male patients who developed inoperable desmoids were given the chemotherapeutic regimen of doxorubicin plus dacarbazine, followed by meloxicam. Significant tumor regression was observed clinically. However, intestinal perforation happened in both patients. They were subjected to emergency surgery, follow-up management, and survived up to now.

Conclusions

The doxorubicin plus dacarbazine chemotherapy is an effective treatment for intra-abdominal demoid tumors in patients with Gardner’s syndrome. On the other hand, given severe adverse events might occur, clinicians should pay more attention that tumor quick regression may cause intestinal perforation in which urgent surgical intervention is necessary.

Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003;21:1698–707.CrossRefPubMed

Hartley JE, Church JM, Gupta S, McGannon E, Fazio VW. Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum. 2004;47:334–40.CrossRefPubMed

Turina M, Pavlik CM, Heinimann K, Behrensmeier F, Simmen HP. Recurrent desmoids determine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years. Int J Colorectal Dis. 2013;28:865–72.CrossRefPubMed

Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, Kerr MC, Hamilton SR. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35:377–81.CrossRefPubMedPubMedCentral

Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.PubMed

Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, Lidsky M, Herman JM, Choti M, Ahuja N, Anders R, Blazer DG 3rd, Gamblin TC, Pawlik TM. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19:4036–42.CrossRefPubMedPubMedCentral

Shapeero LG, De Visschere PJ, Verstraete KL, Poffyn B, Forsyth R, Sys G, Uyttendaele D. Post-treatment complications of soft tissue tumours. Eur J Radiol. 2009;69:209–21.CrossRefPubMed

Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, Oshima T, Fujiwara Y, Gondo N, Tamura K, Utsunomiya J, Hashimoto-Tamaoki T, Yamamura T. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006;24:102–5.CrossRefPubMed

Lynch HT, Fitzgibbons R, Jr., Chong S, Cavalieri J, Lynch J, Wallace F, Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner’s syndrome. Dis Colon Rectum. 1994;37:260–7.CrossRefPubMed

10.

Garbay D, Le Cesne A, Penel N, Chevreau C, Marec-Berard P, Blay JY, Debled M, Isambert N, Thyss A, Bompas E, Collard O, Salas S, Coindre JM, Bui B, Italiano A. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.CrossRefPubMed

11.

Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol. 2011;23:562–9.CrossRefPubMed

12.

Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185–9.CrossRefPubMed

13.

Pinheiro LV, Fagundes JJ, Coy CS, Cabello C, Toro I, Michellino M, Fachina PH, Ward M, Leal RF, Ayrizono Mde L. Multiple desmoid tumors in a patient with Gardner’s syndrome—report of a case. Int J Surg Case Rep. 2014;5:370–4.CrossRefPubMedPubMedCentral

14.

Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, Casali PG, Le Cesne A, Gronchi A, Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRefPubMed

15.

Seow-Choen F. The management of desmoids in patients with familial adenomatous polyposis (Gardner’s syndrome). Acta Chir Iugosl. 2008;55:83–7.CrossRefPubMed

16.

Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612–20.CrossRefPubMed

17.

Berk T, Cohen Z, McLeod RS, Stern HS. Management of mesenteric desmoid tumours in familial adenomatous polyposis. Can J Surg. 1992;35:393–5.PubMed

18.

Soravia C, Sugg SL, Berk T, Mitri A, Cheng H, Gallinger S, Cohen Z, Asa SL, Bapat BV. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol. 1999;154:127–35.CrossRefPubMedPubMedCentral

19.

Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181–90.CrossRefPubMed

20.

Ezumi K, Yamamoto H, Takemasa I, Nomura M, Ikeda M, Sekimoto M, Monden M. Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Jpn J Clin Oncol. 2008;38:222–6.CrossRefPubMed

21.

Yamamoto H, Oshiro R, Nishimura J, Uemura M, Haraguchi N, Hata T, Takemasa I, Mizushima T, Sekimoto M, Doki Y, Mori M. Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors. Oncol Rep. 2013;29:1751–5.PubMed

Title: Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner’s syndrome: report of two cases
Authors: Wei Li
Yuhong Zhou
Qian Li
Hanxing Tong
Weiqi Lu
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-016-0935-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner’s syndrome: report of two cases

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures

A very rare case of a small bowel leiomyosarcoma leading to ileocaecal intussusception treated with a laparoscopic resection: a case report and a literature review

Surgical treatment for pelvic giant cell tumor: a multi-center study

Intramedullary nailing has sufficient durability for metastatic femoral fractures

Diagnostic accuracy of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging of small renal masses in real practice: sensitivity and specificity according to subjective radiologic interpretation

The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined